Ocular Therapeutix Inc.

OCUL | NASDAQ

Price Alert Chart Builder DCF Calculator

$6.97

-$0.34 (-4.65%)

At close: Oct 30, 2026, 4:00 PM ET

$7.13

+$0.16 (+2.30%)

Pre-market: Nov 2, 2026, 7:58 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-4.65%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

42.1

+12.0 pts

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Sector Rank #479/1028 (Top 47%)

Full Analysis

Key Statistics

Market Data

Market Cap $1.53B

1D Range

6.93 7.38

52W Range

6.29 16.11

Valuation (TTM)

PE -4.91

PB 2.94

EV/EBITDA -3.55

Valuation (NTM)

Forward PE N/A

Forward PEG -1.64

Price Target $23.00

Cash Flow

FCF Yield -16.7%

SBC Adj. FCF Yield -20.1%

SBC Impact -20.9%

Margins

Gross Margin 87.1%

Operating Margin -603.0%

FCF Margin -490.1%

Growth (CAGR)

Revenue 3Y | 5Y -1.6% | 10.0%

Dil EPS 3Y | 5Y -8.5% | -8.8%

FCF 3Y | 5Y -45.1% | -36.9%

Returns

ROA -44.9%

ROE -59.9%

ROIC -50.2%

Financial Health

Net Cash

$522.72M

Current Ratio 13.11

Interest Coverage -27.53

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bio...

Sector Healthcare

Industry Biotechnology

Employees 325

IPO Date Jul 25, 2014

Website www.ocutx.com

Fiscal Year January - December

Full Company Profile

Latest News

6 hours ago · globenewswire.com

Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, November 9, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026.

4 days ago · globenewswire.com

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in November 2026.

8 days ago · seekingalpha.com

Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity

Ocular Therapeutix is rated Buy (speculative) with a 12-month price target of $7.90, reflecting a lopsided risk/reward profile. AXPAXLI's strong Phase 3 SOL-1 results support a clear regulatory path, with NDA filing expected in Q4 and potential 2027 launch. The market is pricing in $1.26 billion in peak U.S. sales for OCUL after competitor advances, lost takeover premium, and rising cash burn.

10 days ago · seekingalpha.com

Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript

1 month ago · globenewswire.com

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026.

2 months ago · globenewswire.com

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October 2026.

3 months ago · seekingalpha.com

Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript

3 months ago · benzinga.com

Why Is Ocular Therapeutix Stock Gaining Monday?

Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ:EYPT).

3 months ago · zacks.com

Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.39 per share a year ago.